Results 251 to 260 of about 201,455 (289)

Interferon-Induced Sarcoidosis

JCR: Journal of Clinical Rheumatology, 2006
Rheumatologists are increasingly asked to see patients with hepatitis C who exhibit a variety of clinical and serologic features that mimic systemic rheumatic disease. Treatment with interferons, now the standard of care, can precipitate a variety of inflammatory conditions, including sarcoidosis.
Mittie K, Doyle, Ruth, Berggren, Jeanette H, Magnus   +2 more
openaire   +2 more sources

Interferon-Induced Sarcoidosis

Journal of Computer Assisted Tomography, 2003
Interferons have been used as therapy of both malignant and nonmalignant diseases and commonly in the treatment of hepatitis C virus infection. Although the most commonly encountered side effects of interferon therapy include nonspecific constitutional symptoms, pulmonary involvement is rare.
Ami N, Rubinowitz, David P, Naidich, Cesar, Alinsonorin   +2 more
openaire   +2 more sources

Interferon Inducers

Lancet, The, 1968
exaly   +4 more sources

Interferons and Interferon Inducers

JAMA: The Journal of the American Medical Association, 1973
The fascinating field of the interferons is thoroughly reviewed and brought up to date in this fine volume in the series, Frontiers of Biology . Though a multiauthored presentation, it contains surprisingly little redundancy, a compliment to the editor, N. B. Finter.
openaire   +1 more source

Interferons and interferon-induced antiviral proteins in the testis

Journal of Reproductive Immunology, 1998
Despite the dramatic development of sexually transmissible diseases, the antiviral capabilities of testicular cells have not yet been explored. Interferons (IFNs) are proteins playing a key role in the antiviral defense system, their activity being mediated by several IFN-induced proteins.
N, Dejucq, M O, Liénard, B, Jégou
openaire   +2 more sources

Interferons and Interferon Inducers

Drugs, 1982
Interferons are broadly antiviral, naturally occurring substances, whose exact mechanism of action on virus infections is unknown. Major limitations on the quantities of interferon available for clinical trials have inhibited its development as a therapeutic agent. The variable nature of virus infections in certain patient populations has also produced
openaire   +2 more sources

Synthetic interferon inducers

2007
4. Structural Requirements for Interferon Induction by Synthetic Interferon Inducers . . . . . . . . . . . . . . . . . 183 4.1. Polycarboxylates . . . . . . . . . . . . . . . . 183 4.2. Polynucleotides . . . . . . . . . . . . . . . . . 184 4.2.1. Sufficiently High Molecular Weight . . . . . . . . 184 4.2.2. Stable, Highly Ordered Secondary Structure . .
openaire   +2 more sources

Induction of interferons and interferon-induced genes

Biotherapy, 1996
Type I IFNs (IFN-α, IFN-β, and IFN-ω) are produced in most cell types upon virus infection and upon stimulation by dsRNA (with exceptions of embryonal carcinoma cells which are defective in expressing IFN genes). In addition, certain growth factors and lymphokines such as IL-1, colony stimulating factor (CSF), and TNF also induce type I IFNs.
Charles E. Samuel, Keiko Ozato
openaire   +1 more source

Macrophage Activation by Interferon or Interferon Inducers

1980
There are at least three types of mechanism which singly or in combination may underlie macrophage activation by an administered agent: 1) the agent may directly affect macrophages or macrophage precursors; 2) the agent may trigger the complement, clotting, or plasminogen cascades to generate effector molecules which in turn affect the function of ...
M. Rabinovitch, S. I. Hamburg, E. R. Unanue, M. R. Daha   +3 more
openaire   +1 more source

Interferon and inducers

International Journal of Immunopharmacology, 1985
W. Fiers, R. Devos, W. Degrave, E. Remaut, L. Fransen, J. Tavernier, A. Marmenout   +6 more
  +6 more sources